Yuanqing Lu, Liqun R. Wang, Jungnam Lee, Naweed S. Mohammad, Alek M. Aranyos, Calvin Gould, Nazli Khodayari, Regina A. Oshins, Craig G. Moneypenny, Mark L. Brantly – 26 May 2022 – Alpha‐1 antitrypsin (AAT) deficiency (AATD) is an inherited disease caused by mutations in the serpin family A member 1 (SERPINA1, also known as AAT) gene. The most common variant, PI*Z (Glu342Lys), causes accumulation of aberrantly folded AAT in the endoplasmic reticulum (ER) of hepatocytes that is associated with a toxic gain of function, hepatocellular injury, liver fibrosis, and hepatocellular carcinoma.

25 May 2022

Jagadeesh Menon, Naresh Shanmugam, Mukul Vij, Ashwin Rammohan, Mohamed Rela – 25 May 2022

Bhupinder Kaur, Andres Cardenas, Constantine J. Karvellas – 25 May 2022

Bhupinder Kaur, Andres Cardenas, Constantine J. Karvellas – 25 May 2022

Geethalayam G. Gangadharan, Vinay Mahajan – 25 May 2022

Isabella Lurje, Zoltan Czigany, Sarah Eischet, Jan Bednarsch, Tom Florian Ulmer, Peter Isfort, Pavel Strnad, Christian Trautwein, Frank Tacke, Ulf Peter Neumann, Georg Lurje – 25 May 2022 – Cholangiocarcinoma (CCA) is a rare but highly aggressive malignancy of the biliary system. Although it is amenable to surgical resection in early disease, outcomes are frequently dismal. Here, we investigated the prevalence of body composition (BC) alterations and their prognostic role for surgical patients with intrahepatic (iCCA) and perihilar (pCCA) disease.

Zachary M. Saleh, Elliot B. Tapper – 25 May 2022

Claire Harrington, Swathi Krishnan, Cara L. Mack, Paolo Cravedi, David N. Assis, Josh Levitsky – 24 May 2022 – Autoimmune hepatitis (AIH) is a rare disease of unclear etiology characterized by loss of self‐tolerance that can lead to liver injury, cirrhosis, and acute liver failure. First‐line treatment consists of systemic corticosteroids, or budesonide, and azathioprine, to which most patients are initially responsive, although predictors of response are lacking.

Kazuhiro Murai, Takahiro Kodama, Hayato Hikita, Akiyoshi Shimoda, Makoto Fukuoka, Keisuke Fukutomi, Satoshi Shigeno, Yuto Shiode, Daisuke Motooka, Yuichiro Higuchi, Kei Miyakawa, Hiroshi Suemizu, Akihide Ryo, Yuki Tahata, Yuki Makino, Ryoko Yamada, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara – 23 May 2022 – Current anti–hepatitis B virus (HBV) therapies have little effect on covalently closed circular DNA (cccDNA) and fail to eliminate HBV.